BiotechTube

Eplontersen + Placebo

Phase 3Active
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Transthyretin Amyloid Cardiomyopathy

Conditions

Transthyretin Amyloid Cardiomyopathy

Trial Timeline

Dec 1, 2023 → Jan 5, 2027

NCT ID
NCT06194825

About Eplontersen + Placebo

Eplontersen + Placebo is a phase 3 stage product being developed by AstraZeneca for Transthyretin Amyloid Cardiomyopathy. The current trial status is active. This product is registered under clinical trial identifier NCT06194825. Target conditions include Transthyretin Amyloid Cardiomyopathy.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT06194825Phase 3Active
NCT04136171Phase 3Active

Competing Products

20 competing products in Transthyretin Amyloid Cardiomyopathy

See all competitors
ProductCompanyStageHype Score
Eplontersen Solution for InjectionAstraZenecaPhase 1
33
Eplontersen + PlaceboAstraZenecaPhase 3
77
Treatment of transthyretin (ATTR) amyloidosis in observational study settingAstraZenecaPre-clinical
23
EplontersenAstraZenecaPhase 3
77
NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 3
76
NNC6019-0001Novo NordiskPhase 2
51
NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 2
51
CoramitugNovo NordiskPhase 1
32
TafamidisPfizerPre-clinical
22
TafamidisPfizerPre-clinical
22
tafamidis megluminePfizerApproved
84
Fx-1006APfizerPhase 2
51
TafamidisPfizerPhase 3
76
Tafamidis 61 milligramsPfizerPre-clinical
22
Treatment for TTR amyloidosis + Treatment for TTR amyloidosisPfizerPre-clinical
22
VyndaqelPfizerPre-clinical
22
tafamidisPfizerPhase 3
76
TafamidisPfizerApproved
84
TafamidisPfizerPre-clinical
22
Vyndamax (tafamidis 61mg)PfizerPre-clinical
22

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85